iTeos Therapeutics Completes $75 Million Series B Financing

Gosselies, Belgium – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the completion of an oversubscribed $75 million (€64 million) Series B financing led by MPM Capital, with participation from additional new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All existing investors also participated in this financing round including Fund +, VIVES II and SRIW, as well as SFPI. Read the official press release here.

Read more

ChromaCure raises €17M for its drug discovery program

ChromaCure is a newly created spin-off company of ULB dedicated to develop first-in-class small molecule therapeutics for unmet needs in oncology, based on a very promising target. We are delighted to welcome them in our incubator. Discover the official press release here.

Read more